Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3197804 | Journal of Allergy and Clinical Immunology | 2013 | 11 Pages |
Abstract
These data demonstrate the 5-year durability of the benefits of BT with regard to both asthma control (based on maintained reduction in severe exacerbations and ED visits for respiratory symptoms) and safety. BT has become an important addition to our treatment armamentarium and should be considered for patients with severe persistent asthma who remain symptomatic despite taking inhaled corticosteroids and long-acting β2-agonists.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Michael E. MD, Michel MD, Adalberto S. MD, Jussara MD, Jose R. MD, Pallav L. MD, Elie MD, Ronald MD, Neil C. MD, Robert M. MD, Ian D. MD, Michael MD, Jeff B. MD, Charlene MD, Dirk-Jan MD, Mark MD, Martin J. MD, Serpil C. MD, Mario MD,